一分钟看懂
这是一项关于乳腺癌的II 期研究，登记的药物或干预包括Cromolyn, TQB2102, and Panpulimab，当前状态为尚未开始招募。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Cromolyn, TQB2102, and Panpulimab · II 期
登记条件中文摘要
登记的基本范围为女性，年龄18 岁至70 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fudan University Shanghai Cancer Center · 上海
公开的入选条件
- 1. Age: Female, ≥18 years old and ≤70 years old.
- 2. Diagnosis: Histologically confirmed invasive triple-negative breast cancer (defined as: ER-negative by IHC with \<1% positive tumor cells; PR-negative with \<1% positive tumor cells; HER2 0-1+ or HER2 2+ with confirmed negative FISH/CISH without amplificati
- 3. Prior Treatment: Recurrent or metastatic refractory breast cancer with disease progression after prior immunotherapy.
- 4. Measurable Disease: At least one measurable lesion per RECIST v1.1 (≥20 mm by conventional CT or ≥10 mm by spiral CT; lesion must not have been previously irradiated).
- 5. Organ Function: Adequate organ function as follows:
- 1. Blood Counts: Hemoglobin ≥90 g/L (no transfusion within 14 days); absolute neutrophil count ≥1.5×10⁹/L; platelets ≥75×10⁹/L.
- 2. Blood Chemistry: Total bilirubin ≤1.5×ULN; ALT and AST ≤3×ULN (≤5×ULN if liver metastases are present); serum creatinine ≤1×ULN; creatinine clearance \>50 mL/min (Cockcroft-Gault formula).
- 6. Treatment-Free Interval: No radiotherapy, endocrine therapy, molecular targeted therapy, or major surgery within 3 weeks prior to study entry; recovery from prior treatment-related toxicities (surgical wounds fully healed if applicable); absence of peripher
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07419880；登记信息更新于 2026-09-25。